296 related articles for article (PubMed ID: 25680364)
1. Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.
Bird MF; Vardanyan RS; Hruby VJ; Calò G; Guerrini R; Salvadori S; Trapella C; McDonald J; Rowbotham DJ; Lambert DG
Br J Anaesth; 2015 Apr; 114(4):646-56. PubMed ID: 25680364
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505).
Dietis N; McDonald J; Molinari S; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
Br J Anaesth; 2012 Feb; 108(2):262-70. PubMed ID: 22194444
[TBL] [Abstract][Full Text] [Related]
3. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
4. Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity.
Cai J; Song B; Cai Y; Ma Y; Lam AL; Magiera J; Sekar S; Wyse BD; Ambo A; Sasaki Y; Lazarus LH; Smith MT; Li T
Bioorg Med Chem; 2014 Apr; 22(7):2208-19. PubMed ID: 24613457
[TBL] [Abstract][Full Text] [Related]
5. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
6. Hot topics in opioid pharmacology: mixed and biased opioids.
Azzam AAH; McDonald J; Lambert DG
Br J Anaesth; 2019 Jun; 122(6):e136-e145. PubMed ID: 31010646
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of [Cys(ATTO 488)8]Dermorphin-NH2 as a novel tool for the study of μ-opioid peptide receptors.
Giakomidi D; Bird MF; McDonald J; Marzola E; Guerrini R; Chanoch S; Sabu N; Horley B; Calo G; Lambert DG
PLoS One; 2021; 16(4):e0250011. PubMed ID: 33891604
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.
Dietis N; Guerrini R; Calo G; Salvadori S; Rowbotham DJ; Lambert DG
Br J Anaesth; 2009 Jul; 103(1):38-49. PubMed ID: 19474215
[TBL] [Abstract][Full Text] [Related]
9. In vitro profiling of opioid ligands using the cAMP formation inhibition assay and the β-arrestin2 recruitment assay: No two ligands have the same profile.
Kuo A; Magiera J; Rethwan N; Andersson Å; Leen Lam A; Wyse B; Meutermans W; Lewis R; Smith M
Eur J Pharmacol; 2020 Apr; 872():172947. PubMed ID: 31991138
[TBL] [Abstract][Full Text] [Related]
10. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
11. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
[TBL] [Abstract][Full Text] [Related]
12. Role of Src in ligand-specific regulation of delta-opioid receptor desensitization and internalization.
Hong MH; Xu C; Wang YJ; Ji JL; Tao YM; Xu XJ; Chen J; Xie X; Chi ZQ; Liu JG
J Neurochem; 2009 Jan; 108(1):102-14. PubMed ID: 19014372
[TBL] [Abstract][Full Text] [Related]
13. Opioid receptor binding characteristics and structure-activity studies of novel tetrapeptides in the TIPP (Tyr-Tic-Phe-Phe) series.
Ioja E; Tóth G; Benyhe S; Tourwe D; Péter A; Tömböly C; Borsodi A
Neurosignals; 2005; 14(6):317-28. PubMed ID: 16772734
[TBL] [Abstract][Full Text] [Related]
14. Alterations in the Activity of Spinal and Thalamic Opioid Systems in a Mice Neuropathic Pain Model.
Rojewska E; Wawrzczak-Bargiela A; Szucs E; Benyhe S; Starnowska J; Mika J; Przewlocki R; Przewlocka B
Neuroscience; 2018 Oct; 390():293-302. PubMed ID: 30176322
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia.
Rutten K; Tzschentke TM; Koch T; Schiene K; Christoph T
Eur J Pharmacol; 2014 Oct; 741():264-71. PubMed ID: 25169429
[TBL] [Abstract][Full Text] [Related]
16. Selectivity profiling of NOP, MOP, DOP and KOP receptor antagonists in the rat spinal nerve ligation model of mononeuropathic pain.
Rutten K; Schröder W; Christoph T; Koch T; Tzschentke TM
Eur J Pharmacol; 2018 May; 827():41-48. PubMed ID: 29524385
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive study on the putative δ-opioid receptor (sub)types using the highly selective δ-antagonist, Tyr-Tic-(2S,3R)-β-MePhe-Phe-OH.
Birkas E; Bakota L; Gulya K; Wen T; Pintar J; Tóth G; Szucs M
Neurochem Int; 2011 Aug; 59(2):192-201. PubMed ID: 21672586
[TBL] [Abstract][Full Text] [Related]
18. A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.
Salvadori S; Trapella C; Fiorini S; Negri L; Lattanzi R; Bryant SD; Jinsmaa Y; Lazarus LH; Balboni G
Bioorg Med Chem; 2007 Nov; 15(22):6876-81. PubMed ID: 17851080
[TBL] [Abstract][Full Text] [Related]
19. Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.
Fujita W; Gomes I; Devi LA
Br J Pharmacol; 2015 Jan; 172(2):375-87. PubMed ID: 24571499
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and pharmacological characterization of a novel, highly potent, peptidomimetic delta-opioid radioantagonist, [3H]Tyr-Tic-(2S,3R)-beta-MePhe-Phe-OH.
Birkas E; Kertesz I; Toth G; Bakota L; Gulya K; Szucs M
Neuropeptides; 2008 Feb; 42(1):57-67. PubMed ID: 18068762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
